
MDAI Stock Forecast & Price Target
MDAI Analyst Ratings
Bulls say
Spectral AI Inc is poised for substantial financial growth, with expectations for revenue to increase at a compound annual growth rate (CAGR) of 69% or more from FY26 through FY30, following the commercial launch of its DeepView System. The company has also improved its research and development revenue forecasts significantly, projecting revenues of $18.5 million for FY26, a substantial increase from prior estimates. Additionally, Spectral AI's licensing model is anticipated to generate recurring revenue at high margins, positioning the company favorably for stable and predictable growth in the MedTech industry.
Bears say
Spectral AI Inc has reduced its FY25 BARDA revenue guidance to approximately $18.5 million, reflecting a year-over-year decline of 37.6% from the prior $21.5 million forecast, primarily due to timing issues with the BARDA contract and the impact of a government shutdown. The company anticipates further revenue declines in FY26, having not provided specific guidance but indicating that revenue is expected to be lower than FY25 levels. Additionally, the potential for extended clinical and regulatory development timelines poses a risk to future BARDA-related revenue, further contributing to a negative financial outlook for Spectral AI.
This aggregate rating is based on analysts' research of Spectral AI Inc and is not a guaranteed prediction by Public.com or investment advice.
MDAI Analyst Forecast & Price Prediction
Start investing in MDAI
Order type
Buy in
Order amount
Est. shares
0 shares